EGFR and ovarian carcinoma: This evidence prompted the development of several strategies to target EGFR and HER2: monoclonal antibodies directed against the extracellular domain of the receptors or small molecules targeting the intracellular tyrosine kinase domains (tyrosine kinase inhibitors (TKIs)) are in various stages of clinical trials for ovarian cancer [60].